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Background: Several peripheral proteins that might be useful for detecting the presence of ectopic pregnancy (EP)
have been evaluated, but none have been proven entirely useful in the clinic. We investigated the presence and
the possible changes in circulating molecules that distinguish between normal intrauterine pregnancy (IUP) and
tubal ectopic pregnancy.
Methods: Non-pregnant women during the menstrual cycle, women with IUP, and women with tubal EP after
informed consent. Serum levels of 17β-estradiol (E2), progesterone (P4), testosterone (T), beta-human chorionic
gonadotropin (β-hCG), vascular endothelial growth factor-A (VEGF-A), placental growth factor (PIGF), and a
distintegrin and metalloprotease protein 12 (ADAM12) were analyzed. Receiver operating characteristic analysis was
used to assess the diagnostic discrimination of EP and gestational age-matched IUP.
Results: E2, P4, PIGF, and ADAM12 levels increased and β-hCG decreased throughout IUP. E2 and VEGF-A levels
were significantly different between women with tubal EP and IUP. However, using a serum β-hCG cut-off of less
than 1000 mIU/mL, P4 was significantly lower in women with tubal EP compared to IUP. Although E2 was inversely
correlated with VEGF-A in women in the early stages of IUP, E2 was not correlated with VEGF-A in women with EP
prior to tubal surgery. There were no significant differences in either PIGF or ADAM12 alone between women with
tubal EP or IUP. Although no significant correlations were seen between E2 and PIGF or P4 and ADAM12 in women
in the early stages of IUP, E2 was positively correlated with PIGF and P4 was positively correlated with ADAM12 in
women with EP prior to tubal surgery. Our studies defined associations but not causality.
Conclusions: Individual measurements of serum E2 or VEGF-A levels are strongly related to early pregnancy
outcomes for women with IUP and EP, and pregnancy-associated E2 and VEGF-A levels provide diagnostic accuracy
for the presence of tubal EP. This study demonstrates that correlation analysis of E2/VEGF-A and E2/PIGF serum
levels may be able to distinguish a tubal EP from a normal IUP.
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Approximately 98% of ectopic pregnancies (EP) occur in
the Fallopian tube [1]. The most significant complication
of EP is rupture of the Fallopian tube causing massive
internal bleeding, infection, and possibly death [2]. EPs
are asymptomatic prior to rupture of the Fallopian tube
[2,3] and at present the only way to conclusively diagnose* Correspondence: ruijin.shao@fysiologi.gu.se
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reproduction in any medium, provided the orEP is transvaginal ultrasound monitoring, preferably with
β-human chorionic gonadotropin (β-hCG) and progester-
one (P4) confirmation [3]. Although symptom-based diag-
nosis of tubal EP has improved [1,4], the diagnosis of EP is
not always simple or straightforward. It has been reported
that more than one-third of the women who have died
from EP in the UK since 1997 had been mis-diagnosed
[4]. Although several risk factors for tubal EP have been
identified [5-8], the underlying mechanisms leading to
tubal EP are not fully understood [1,9]. There is currently
no accurate method to identify what treatments for tubal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cause an early and accurate laboratory diagnosis of tubal
EP could assist clinical management, various laboratories
have directed their research toward biochemical markers
of tubal EP [10-13]. Several peripheral proteins that might
be useful for detecting the presence of EP have been
evaluated [14,15], but none have been proven entirely use-
ful in the clinic.
The vascular endothelial growth factor (VEGF) family
consists of VEGF-A (generally called VEGF), VEGF-B,
VEGF-C, VEGF-D, VEGF-E, and placental growth factor
(PIGF). These are angiogenic factors that participate in
the regulation of early placental angiogenesis and ma-
ternal spiral artery remodeling [16]. A disintegrin and
metalloprotease protein 12 (ADAM12) is one member
of a disintegrin and metalloprotease protein family that
possesses extracellular metalloprotease and cell-binding
functions as well as intracellular signaling capacities [17].
Although the mechanisms underlying the functional roles
of VEGF-A, PIGF, and ADAM12 in tubal EP are not clear,
circulating levels of VEGF-A [12,18-23], PIGF [23-25],
and ADAM12 [26-28] have been shown to change in
women with EP. However, the retrospective case–control
studies have yielded inconsistent results for such
correlations [24,27,29]. The regulatory effects of changes
in reproductive steroid hormones or of menstrual cycle
phase on the circulating levels of VEGF-A, PIGF, and
ADAM12 in women throughout normal intrauterine
pregnancy (IUP) and post-term delivery are far less stud-
ied and understood. Furthermore, to our knowledge there
are no studies making direct comparisons of these candi-
date protein biomarkers for EP diagnosis within the same
cohort.
It has long been recognized that early diagnosis is im-
portant for making therapeutic decisions in regards to
tubal EP that improve future fertility. Because the measure-
ment of candidate biomarkers in the circulation is a
noninvasive procedure and is relatively simple to perform
without requiring special instruments and personnel, the
development and validation of circulating biomarkers for
the early diagnosis of tubal EP is warranted. The present
study aimed to evaluate whether circulating hormone (17β-
estradiol (E2), progesterone (P4), testosterone (T), and β-
hCG), VEGF-A, PIGF, and ADAM12 levels vary in women
during the menstrual cycle, in women with IUP, and in
women with EP before and after tubal surgeries.
Methods
Ethics statement
This study was approved by the Ethics Committees of the
Obstetrics and Gynecology Hospital and Shanghai Medical
College, Fudan University, China. All participants provided
informed consent.Study design and sample collection
All participants underwent clinical examination at the
Obstetrics and Gynecology Hospital of Fudan University,
Shanghai, China. Clinical work-up included menstrual
history as well as current cycle length and menstrual
regularity.
Exclusion criteria included use of estrogen- or progestin-
containing medication within three months of the study,
past EP, any gynecological pathology (e.g., endometriosis,
fibroids, or any operation to the gynecological organs), in-
fection, and smoking. All the patients whose pregnancies
resulted from assisted reproductive technologies were also
excluded from the study.
Blood samples were collected into Sarstedt evacuated
tubes without anticoagulant. All blood samples were
centrifuged at 1000× g for 15 min, and the serum was
stored at −80 ° C until batch analyses. The present study
included non-pregnant and pregnant women (total n =
153) who were subdivided into the following groups:
Group 1. The different stages of the menstrual cycle in
non-pregnant women (n = 78) were studied. Blood
samples were collected at the scheduled visits during their
menstrual cycle. Menstrual cycle day was established
using the criteria reported by Noyes et al. [30]. Sample
dating characterized the samples as coming from the
proliferative (days 1–14 of the cycle), early secretive (days
15–18), mid-secretive (days 19–23), and late secretive
(days 24–28) phases of the menstrual cycle. Regular men-
strual cycles were defined as an average cycle length of
26–30 days, with no more variation than ± 3 days from
the average. Transabdominal ultrasonography was also
performed to assess ovarian volume and uterine thickness.
Group 2. This group comprised healthy pregnant women
studied longitudinally throughout gestation and post-term
delivery (n = 42). Blood samples were collected at the
scheduled visits during their IUP, and on days 1–3 after
spontaneous labor and vaginal delivery. The diagnosis of a
normal IUP was made upon the observation of an intra-
uterine gestational sac or a live embryo on the transvaginal
or transabdominal ultrasound scan. Only women with nor-
mally progressing pregnancies were studied during their
visits to the prenatal clinic during the early, middle, and late
stages of their IUP.
Group 3. In this group, women with EP (n = 32) were
studied before and after tubal surgery and matched to a
subgroup of women with early IUP. A full medical history
was documented, and clinical examination was carried
out by the attending physician. Transvaginal ultrasonog-
raphy was performed and the serum β-hCG levels were
analyzed in patients at the time of their first clinical presen-
tation. Blood samples were collected from patients at the
time of surgery or 2–3 days after surgery. None of the
women undergoing surgical management of EP presented
with acute hemodynamic shock. Women with EP were
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ation of the surgical specimens.
Main outcome measures
All sera were stored at −80°C before performing the
assays, and aliquots that had not been previously thawed
were used in the present study. Samples were tested in du-
plicate and analyzed individually. Radioimmunoassays
(RIA) were performed at Beijing Free Co. (China), and
enzyme-linked immunoassays (ELISA) were performed at
the Department of Integrative Medicine and Neurobiol-
ogy, Shanghai Medical College, Fudan University (China).
The averages of the duplicate readings for each standard,
control, and individual samples were used for the analyses.
E2, P4, T, and β-hCG assays
Serum E2 (with an assay sensitivity less than 5.0 pg/mL,
an intra-assay coefficient of variation (CV) of 10.0%, and
an interassay CV of 15.2%), P4 (with an assay sensitivity
less than 5.0 ng/mL, an intra-assay CV of 5.0%, and an
interassay CV of 10.0%), T (with an assay sensitivity less
than 0.1 ng/mL, an intra-assay CV of 8.0%, and an
interassay CV of 15.0%), and β-hCG (with an assay sensitiv-
ity less than 10.0 mIU/mL, an intra-assay CV of 5.0%, and
an interassay CV of 10.0%) levels were measured by com-
petitive RIA (125I - Kit, Beijing Free Co.) using direct-
coated tube technology. E2, P4, T, and β-hCG were la-
beled with 125I as the tracer, and known quantities of
unlabeled E2, P4, T, and β-hCG were used to construct
standard curves. The concentrations used for the stand-
ard curves were 0–4000 pg/mL for E2, 0–100 ng/mL for
P4, 0–10 ng/mL for T, and 0–1600 mIU/mL for β-hCG.
VEGF-A, PIGF, and ADAM12 assays
All samples were brought to room temperature and
vortexed for 5 s before applying them to the ELISA
plate. Serum levels of VEGF-A (with an assay sensitivity
less than 5.0 pg/mL, an intra-assay CV of 6.7%, and an
interassay CV of 8.8%), PIGF (with an assay sensitivity
less than 7.0 pg/mL, an intra-assay CV of 7.0%, and an
interassay CV of 11.8%), and ADAM12 (with an assay
sensitivity less than 0.03 ng/mL, an intra-assay CV of
4.1%, and an interassay CV of 5.5%) were measured by
ELISA. The ELISA kits for the three proteins were cata-
log numbers DVE00, DPG00, and DAD120, respectively,
from R&D Systems, Inc., Minneapolis, MN. Assays were
performed as described previously [21,25,27] according
to the manufacturer’s instructions and with reagents and
materials provided by the manufacturer.
Statistical analysis
Numerical, grouped results are expressed as the mean ±
SEM. In all analyses, a P value less than 0.05 was considered
statistically significant. Statistical analysis was performedusing SPSS version 16.0 for Windows (SPSS Inc., Chicago,
IL). Comparison among the various groups was performed
using nonparametric tests (Kruskal-Wallis followed by
multiple comparison procedures according to Dunn’s
method) because our variables did not have a normal distri-
bution. Correlation between variables was performed using
Spearman’s analysis.
The specificity and sensitivity of the various assays as
diagnostic tests were assessed using receiver operating
characteristic (ROC) curve analysis [31]. As opposed to ac-
curacy, sensitivity and specificity are not dependent on the
prevalence of the disease in the sample. Thus, ROC curve
analysis provides a description of disease detectability that
is independent of both disease prevalence and decision
threshold effects. For ROC analysis, women with EP were
considered affected, and IUP as unaffected. ROC curves
were constructed by plotting the sensitivity (true-positive)
on the ordinate as a function of the complement of specifi-
city (false-positive) for all possible cut-off values of the diag-
nostic test [32]. Greater deviation toward the left upper
corner of the curve indicates better detection of EP.
Results
The demographics and laboratory characteristics of the
normal menstrual cycle women and those with IUP and
EP are shown in Table 1 and 2. There were no signifi-
cant differences in age between the three groups and
there were also no significant differences in the number
of gestational days in women with EP and early IUP.
Consequently, we examined the relationships between
hormones and VEGF-A, PIGF, and ADAM12 in these
groups using unadjusted Spearman’s analysis (Tables 3, 4
and 5).
The menstrual cycle
Although a nonparametric, unpaired Kruskal-Wallis test
did not show significant differences between the four endo-
metrial cycle phases, serum E2 and P4 levels exhibited
characteristic changes during the menstrual cycle. The E2:
P4 ratio was significantly decreased in the early-, mid-, and
late-secretive phases compared to the proliferative phase
(Table 1). However, no significant differences in serum T,
VEGF-A, PIGF, or ADAM12 levels were observed between
any of the phases (Table 1 and 2). There was no significant
correlation between steroid hormones (E2, P4, and T) and
candidate biomarkers (VEGF-A, PIGF, and ADAM12) in
the mid-secretive phase (Tables 3, 4 and 5).
IUP
Although serum T levels were not significantly different
between early, middle, and late stages of IUP and post-
term delivery, serum E2 and P4 levels increased progres-
sively during these stages, peaked in the late stage of
IUP, and fell after delivery. Serum β-hCG levels were
Table 1 Patient characteristics and hormonal profiles
n Age GA E2 P4 E2/P4 T β-hCG
(years) (days) (pg/mL) (ng/mL) (ng/mL) (mIU/mL)
Menstrualcycle phase
Proliferative 30 25.90 ± 0.50 – 37.99 ± 4.76 0.90 ± 0.12 0.06 ± 0.012 0.21 ± 0.02 –
Early secretive 13 25.85 ± 0.55 – 16.84 ± 4.52 2.59 ± 0.82 0.01 ± 0.004▲ 0.15 ± 0.02 –
Mid secretive 20 25.10 ± 0.40 – 14.57 ± 4.15 5.05 ± 1.02 0.02 ± 0.008▲▲ 0.15 ± 0.05 –
Late secretive 15 25.80 ± 1.09 – 14.83 ± 2.97 3.80 ± 1.15 0.01 ± 0.003▲▲ 0.15 ± 0.04 –
Intrauterine pregnancy
Early 14 26.36 ± 1.46 50.57 ± 1.36 176.61 ± 21.87 13.00 ± 1.65 0.02 ± 0.003 0.53 ± 0.05 21320.76 ± 1700.47
Middle 10 27.33 ± 1.03 115.50 ± 4.06 211.91 ± 42.04 15.81 ± 1.03 0.01 ± 0.003 0.27 ± 0.05 17727.61 ± 2925.63
Late 13 27.58 ± 1.08 255.11 ± 8.16 499.62 ± 87.98### 89.93 ± 11.99 ### 0.01 ± 0.003 0.70 ± 0.08 12311.79 ± 1644.37##
Post-term delivery 10 30.70 ± 1.27 – 39.86 ± 5.35 6.62 ± 0.74 0.01 ± 0.001 0.37 ± 0.04 3691.29 ± 816.94 ###
Ectopic pregnancy
Before surgery
β-hCG< 1,000mIU/mL 17 29.06 ± 1.13 48.00 ± 4.31 36.09 ± 5.00 3.65 ± 0.77 0.02 ± 0.003 0.41 ± 0.05 813.45 ± 350.12
β-hCG ≥ 1,000mIU/mL 15 31.93 ± 1.56 47.20 ± 3.87 33.31 ± 6.45 6.97 ± 1.30 0.01 ± 0.008* 0.48 ± 0.04 6505.13 ± 1999.57
Total 32 30.41 ± 0.96 47.61 ± 2.86 34.70 ± 4.01 5.37 ± 0.82 0.02 ± 0.004 0.45 ± 0.03 3573.05 ± 1092.31
After surgery
β-hCG< 500mIU/mL 16 29.13 ± 1.28 – 54.53 ± 15.90 2.04 ± 0.38 0.03 ± 0.006* 0.37 ± 0.06 237.15 ± 36.15
β-hCG ≥ 500mIU/mL 6 29.50 ± 1.73 – 26.03 ± 9.77 2.43 ± 0.38 0.01 ± 0.003 * 0.26 ± 0.07 1792.07 ± 353.56
Total 22 29.23 ± 1.02 – 46.75 ± 12.05 2.14 ± 0.29 0.02 ± 0.005 0.34 ± 0.05 703.63 ± 192.92
GA, gestational age. Data are presented as mean ± SEM. Statistical analysis was performed using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL).
A nonparametric, unpaired test (Kruskal-Wallis test) followed by Dunnett'spost hoc test was used for comparison of continuous variables.
▲ p<0.05, ▲▲ p<0.01 vs. the proliferative phase of the endometrial cycle; ## p<0.01, ### p<0.001 vs. the early stage of intrauterine pregnancy;
* p<0.05 vs. ectopic pregnancy (before surgery, β-hCG< 1,000mIU/mL).
Zou et al. Journal of Translational Medicine 2013, 11:44 Page 4 of 12
http://www.translational-medicine.com/content/11/1/44high in the early stage of IUP and decreased throughout
IUP and post-term delivery. Serum PIGF and ADAM12
levels also became progressively higher throughout the
course of IUP, and were highest in the late stage of IUP
(Table 2). Serum levels of PIGF and ADAM12 decreased
after delivery. No significant changes in the E2:P4 ratio
or serum T and VEGF-A levels were observed (Table 1
and 2), but there was a significant correlation between
serum E2 and VEGF-A levels in the early stages of IUP
(r = −0.67, P < 0.01) (Table 3).
Differences between IUP and the mid-secretive phase of
the menstrual cycle
Serum E2 and T levels were significantly higher in the
early stage of IUP than in the mid-secretive phase of the
menstrual cycle (Figure 1A and C). Serum ADAM12
levels were also significantly higher in women with nor-
mal IUP post-term delivery than in women in the mid-
secretive phase of the menstrual cycle (Figure 1F).
Tubal EP
Table 1 lists the variations in the serum β-hCG levels in
women with EP before and after tubal surgeries.Significant differences in the E2:P4 ratios were only
observed when using two different cut-off values (500
and 1000 mIU/mL, Table 2). Because the variations in
the serum concentrations of E2, P4, T, VEGF-A, PIGF
and ADAM12 did not differ in women with EP with dif-
ferent β-hCG levels within the same surgical group, the
results of the two EP subgroups before or after tubal sur-
gery are presented as a total group (Tables 3, 4 and 5,
Figure 1 and 2). In contrast to women with EP prior to
tubal surgery, serum E2 levels were correlated with
serum VEGF-A and ADAM12 levels after tubal surgery
(r = −0.43, P = 0.05 (Table 3) and r = −0.45, P = 0.04
(Table 5), respectively). Serum E2 levels were signifi-
cantly correlated with serum PIGF levels in women with
EP both before (r = 1.00, P < 0.001) and after (r = −0.48,
P = 0.03) tubal surgeries (Table 4). In contrast to E2,
serum P4 levels were significantly correlated with serum
ADAM12 levels in women with EP prior to tubal sur-
gery (r = 1.00, P < 0.001) (Table 5). Serum T levels
correlated well with serum VEGF-A levels in women
with EP prior to tubal surgery (r = 0.46, P = 0.04)
(Table 3) and with serum PIGF levels after tubal surgery
(r = −0.44, P = 0.05) (Table 4).
Table 2 Patient VEGF-A, PIGF, and ADAM12 levels
n VEGF-A PIGF ADAM12
(pg/mL) (pg/mL) (ng/mL)
Menstrualcycle phase
Proliferative 30 420.74±31.75 49.64±1.12 0.94±0.06
Early secretive 13 391.59±50.64 49.16±3.52 1.41±0.13
Mid secretive 20 389.00±43.50 64.08±8.32 1.19±0.15
Late secretive 15 284.57±26.72 79.95±10.05 0.43±0.04
Intrauterine pregnancy
Early 14 169.29±59.77 43.05±1.06 2.35±0.70
Middle 10 91.33±3.30 363.42±160.63### 20.43±3.97
Late 13 95.13±4.68 517.87±85.97### 83.12±13.96###
Post-term delivery 10 661.67±192.11 46.22±1.30 41.81±4.49###
Ectopic pregnancy
Before surgery
β-hCG< 1,000mIU/mL 17 655.76±56.30 43.88±1.11 1.35±0.24
β-hCG ≥ 1,000mIU/mL 15 1095.56±185.03 41.03±1.49 1.61±0.29
Total 32 853.67±99.62** 42.60±0.94 1.46±0.18
After surgery
β-hCG< 500mIU/mL 16 1080.63±150.38 44.99±1.29 1.33±0.06
β-hCG ≥ 500mIU/mL 6 1584.67±234.67 46.31±1.18 1.42±0.06
Total 22 1200.63±133.60*** 45.30±1.02 1.35±0.05
Data are presented as mean ± SEM. Statistical analysis was performed using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL). A nonparametric, unpaired test
(Kruskal-Wallis test) followed by Dunnett'spost hoc test was used for comparison of continuous variables. ### p<0.001 vs. the early stage of intrauterine
pregnancy; ** p< 0.01, *** p< 0.001 vs. ectopic pregnancy (before surgery, β-hCG< 1,000).
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phase of menstrual cycle
Serum T levels were significantly higher in women with
EP before tubal surgery than in women in the mid-
secretive phase of the menstrual cycle (Figure 1C).
Serum VEGF-A levels were significantly higher in
women with EP both before and after tubal surgeries
than in women in the mid-secretive phase of the men-
strual cycle (Figure 1D).Table 3 Correlation between VEGF-A level and hormone conc
E2
Endometrial cycle phase
Mid secretive −0.08 (0.75)
Intrauterine pregnancy
Early −0.67 (0.01)
Post-term delivery 0.42 (0.27)
Ectopic pregnancy
Before surgery 0.06 (0.80)
After surgery −0.43 (0.05)
The results are shown as the r-value of the Spearman correlation at p < 0.01 andth
parentheses and boldface values are statistically significant.
n.d., not determined.Differences between tubal EP and gestational age-
matched IUP
Women with EP both before and after tubal surgeries
had lower levels of E2 than the gestational age-matched
women with IUP (Figure 1A). The mean difference in E2
levels between tubal EP before surgery and the early
stage of IUP was 139.73 pg/mL (95% CI: 95.14–184.31,
P < 0.001). There were no significant differences in serum
P4 levels in tubal EP compared with the early stage ofentrations
P4 T β-hCG
0.05 (0.83) −0.25 (0.30) n.d.
−0.19 (0.53) −0.29 (0.34) 0.14 (0.65)
−0.18 (0.64) −0.42 (0.26) −0.53 (0.12)
−0.25 (0.29) 0.46 (0.04) −0.06 (0.85)
−0.29 (0.20) −0.34 (0.13) 0.36 (0.13)
e 95% confidence interval. The significance (P value) of the correlation is in
Table 4 Correlation between PIGF level and hormone concentrations
E2 P4 T β-hCG
Endometrial cycle phase
Mid secretive −0.17 (0.48) 0.10 (0.69) 0.04 (0.87) n.d.
Intrauterine pregnancy
Early −0.01 (0.99) 0.48 (0.10) −0.29 (0.34) −0.06 (0.85)
Post-term delivery 0.25 (0.52) 0.13 (0.73) −0.25 (0.52) −0.23 (0.52)
Ectopic pregnancy
Before surgery 1.00 (<0.001) −0.13 (0.57) −0.30 (0.19) −0.04 (0.87)
After surgery −0.48 (0.03) −0.11 (0.65) −0.44 (0.05) 0.09 (0.71)
The results are shown as the r-valueof the Spearman correlation at p < 0.01 and a 95% confidence interval. The significance (P value) of the correlation is in
parentheses and boldface values are statistically significant.
n.d., not determined.
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β-hCG cut-off level (<1000 mIU/mL) showed a signifi-
cant difference in P4 levels between women with tubal
EP with less than 1000 mIU/mL β-hCG and women in
the early stage of IUP (3.65 ± 0.77 vs. 13.00 ± 1.65
mIU/mL, P < 0.001). The levels of serum β-hCG were
significantly lower in women with tubal EP than in
women in the early stage of IUP (Table 1). Women
with EP both before and after tubal surgeries had
higher levels of VEGF-A than in the gestational age-
matched women with IUP (Figure 1D). The mean differ-
ence in VEGF-A levels between tubal EP prior to surgery
and the early stage of IUP was 684.38 pg/mL (95% CI:
420.54–948.22, P < 0.001). However, no significant
differences in T, PIGF, or ADAM12 levels alone were
observed between women with tubal EP and gestational
age-matched women with IUP (Figures 1C, E and F).
The diagnostic accuracy of the various parameters (E2,
P4, T, VEGF-A, PIGF, and ADAM12 levels and the E2:
P4 ratio) in the tubal EP and early IUP groups was
evaluated by ROC analysis (Figures 2A and B). The area
under the ROC curve represents the probability of cor-
rectly distinguishing between gestational age-matched
women with tubal EP or IUP. The areas under theTable 5 Correlation between ADAM12 level and hormone con
E2
Endometrial cycle phase
Mid secretive −0.33 (0.15)
Intrauterine pregnancy
Early 0.36 (0.22)
Post-term delivery 0.12 (0.77)
Ectopic pregnancy
Before surgery −0.13 (0.57) 1
After surgery −0.45 (0.04)
The results are shown as the r-value of the Spearman correlation at p < 0.01 anda 9
parentheses and boldface values are statistically significant.
n.d., not determined.curves for serum E2, P4, and VEGF-A levels for the
diagnosis of tubal EP were 0.99 (95% CI: 0.98–1.00, P <
0.0001), 0.86 (95% CI: 0.75–0.98, P < 0.0001), and 0.94
(95% CI: 0.86–1.00, P < 0.0001), respectively. However,
the areas under the curves for serum T, PIGF, and
ADAM12 levels for the diagnosis of tubal EP were 0.61
(95% CI: 0.42–0.80, P > 0.05), 0.47 (95% CI: 0.26–0.68,
P > 0.05), and 0.48 (95% CI: 0.25–0.69, P > 0.05), re-
spectively. These ROC curve analyses showed that the
identification of women with tubal EP could not rely
on measurements of serum levels of T, PIGF, or
ADAM12 alone. In addition, the areas under the
curves for the E2: VEGF-A and E2: PIGF ratios for
the diagnosis of tubal EP were 0.99 (95% CI: 0.97–
1.00, P < 0.001) and 1.00 (95% CI: 1.00–1.00, P < 0.001),
respectively (Figure 2C).Discussion
There is a need for a sensitive and specific diagnostic bio-
marker that can facilitate early diagnosis and permit timely
treatment of tubal EP [14,15]. Currently, the limited specifi-
city and sensitivity of circulating biomarkers for the early
diagnosis of tubal EP has greatly restricted their reliability.centrations
P4 T β-hCG
−0.23 (0.33) 0.11 (0.63) n.d.
−0.34 (0.26) 0.53 (0.06) 0.07 (0.82)
−0.43 (0.24) 0.38 (0.31) 0.18 (0.63)
.00 (<0.001) 0.15 (0.54) −0.31 (0.18)
−0.20 (0.40) −0.36 (0.11) 0.19 (0.43)












































































































































































Figure 1 Serum levels of E2, P4, T, VEGF, PIGF, and ADAM12 in women with IUP divided into early IUP and post-term delivery
subgroups, and in women with EP before and after tubal surgeries compared with women in the mid-secretive phase of the
endometrial cycle. All data are expressed as the mean ± SEM. A nonparametric, unpaired test (Kruskal-Wallis test) followed by Dunnett's post-
hoc test was used for multiple comparisons of continuous variables. ** P<0.01, and *** P<0.001. n.s., not significant.
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http://www.translational-medicine.com/content/11/1/44The present study has significant strengths. First, this
study shows in an independent and well-defined sample
set that individual measurements of serum P4 levels
were lower in women with tubal EP than gestational
age-matched women with IUP, but this difference was
not statistically significant. Sub-group analysis, however,
provided a much more striking result. When samples
were compared at a serum β-hCG level of less than 1000
mIU/mL, serum P4 levels differed significantly between
the tubal EP and gestational age-matched IUP groups.
These results suggest that using a combination of
serum P4 and β-hCG levels can possibly differentiate a
certain group of women with tubal EP from those withnormal IUP. More importantly, we show that individ-
ual measurements of serum E2 or VEGF-A levels have
significant advantages over serum P4 levels for
distinguishing tubal EP from gestational age-matched
IUP. Our data, together with that provided by others
[15,33], show that circulating E2 levels are higher in
women with tubal EP than non-pregnant women in
the mid-secretive phase of the menstrual cycle, but are
lower than in gestational age-matched women with
IUP. These findings indicate that abnormal E2 levels
may interrupt the tubal microenvironment and ultim-
ately lead to improper embryo implantation in the Fal-







Figure 2 (See legend on next page.)
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Figure 2 (A) E2, P4, T levels and the E2:P4 ratio as diagnostic tests for women with tubal EP were assessed by the receiver operating
curve (ROC) test. ROC analysis was performed with SPSS version 16.0 for Windows, and statistical significance (P value) is indicated. The area
under the curve was 0.99 (95% CI: 0.98–1.00) for E2, 0.86 (95% CI: 0.75–0.98) for P4, 0.61 (95% CI: 0.42–0.80) for T, and 0.67 (95% CI: 0.51–0.83) for
the E2:P4 ratio. (B) VEGF, PIGF, and ADAM12 as diagnostic tests for women with tubal EP were assessed by the ROC test. The area under the
curve was 0.94 (95% CI: 0.86–1.00) for VEGF, 0.47 (95% CI: 0.26–0.68) for PIGF, and 0.48 (95% CI: 0.25–0.69) for ADAM12. (C) The E2: VEGF-A and E2:
PIGF ratio as diagnostic tests for women with tubal EP were assessed by the ROC test. The area under the curve was 0.99 (95% CI: 0.97–1.00) for
the E2: VEGF-A ratio, and 1.00 (95% CI: 1.00–1.00) for the E2: PIGF ratio.
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http://www.translational-medicine.com/content/11/1/44despite differences in the study populations, we have
found a significant induction in VEGF-A levels in
women with EP relative to gestational age-matched
women with IUP. Using an increased cut-off of
200 pg/mL, we have shown that all women with tubal
EP (n = 33) had a serum VEGF-A level more than
200 pg/mL, which is consistent with previous studies
[18,21]. The data indicate that a serum VEGF-A level
of greater than 200 pg/mL can be used to discriminate
a tubal EP from a normal IUP in women. Additionally,
we found that serum E2 and VEGF-A concentration
measurements generated superior diagnostic accuracy.
Taken together, these data suggest that E2 and VEGF-
A can be useful biomarkers for the early diagnosis of
tubal EP.
The second important finding of the present study is
that there are different correlations between the levels
of steroid hormones and VEGF-A, PIGF, and ADAM12
in both the early stage of IUP and in tubal EP. This
suggests that their in vivo biological functions should
not be considered independently of each other. We
show that, in contrast to the early stage of IUP, serum
E2 levels do not correlate with serum VEGF-A levels
but do correlate with serum PIGF levels in tubal EP.
We also show that serum T levels correlate with
serum VEGF-A levels and that serum P4 levels correl-
ate with serum ADAM12 levels in tubal EP. Although
highly suggestive, these significantly correlated data
cannot prove that steroid hormones are responsible for
the changes in the levels of VEGF-A, PIGF, and
ADAM12 in the Fallopian tube. Embryonic implant-
ation in the uterus is a complex developmental process
that is likely mediated by a variety of molecules such
as steroid hormones, growth factors, and cytokines
[34]. However, little is known about the interactions of
these molecules, especially in terms of tubal implant-
ation [5,9]. Previous studies have demonstrated the use of
combinations of circulating proteins for the diagnosis of EP
[12,22], and we show here that the E2: VEGF-A and E2:
PIGF ratios can aid in distinguishing tubal EP from normal
IUP. It will be of interest in future studies to validate the
results from our study with additional cohorts and to deter-
mine whether alternative combinations of these markers
may demonstrate improved performance.Possible mechanisms responsible for the regulation of
VEGF/PIGF expression, secretion, and signaling pathways
during the development of tubal EP
To grow to the point of causing harm, a tubal EP
requires the development of a local blood supply and
angiogenesis at the tubal implantation site. It is thus rea-
sonable to expand upon clinical research on circulating
VEGF isoforms to understand the mechanisms by which
their synthesis is regulated and to understand their bio-
logical functions during Fallopian tubal implantation.
Such research would allow for a better understanding of
the actual diagnostic values of VEGF-A and PIGF. In the
human Fallopian tube, VEGF is localized in the epithelial
cells, smooth muscle cells, and blood vessel cells in a
region-specific manner [35,36], and significantly higher
levels of tubal VEGF and VEGF receptor mRNAs are
detected in women with a hydrosalpinx [37], which is
defined as tubal dilation and abnormal fluid accumula-
tion [6]. Moreover, in vitro studies have shown an in-
crease in VEGF and soluble VEGF receptor secretion in
human tubal epithelial cells and stromal fibroblasts in
response to hypoxic stimulation [38]. It has been shown
that VEGF-A and VEGF receptor mRNAs are signifi-
cantly increased in the implantation site compared to
non-implantation sites of human Fallopian tubes [39],
and these are associated with trophoblastic invasion into
the tubal wall in vivo [40] suggesting that the develop-
ment of tubal EP could contribute to the elevation of cir-
culating VEGF-A levels. Moreover, ligation of the
Fallopian tube, which mimics the tubal occlusion that
likely induces an EP in women, increases VEGF protein
expression in rat Fallopian tubes [41].
Our results, together with those from other laborator-
ies, provide a basis for proposing a working model for
regulation and activation of VEGF isoforms and their re-
ceptor signaling pathways during tubal implantation.
Disruption of the local environment such as a low oxy-
gen level, possibly due to embryo implantation in the
Fallopian tube, induces elevated levels of hypoxia-
inducible factors (HIFs) [42]. This leads to tubal VEGF-
A synthesis and secretion resulting in the abnormal
levels of circulating VEGF-A seen in women with EP.
HIF, a critical hypoxia sensor, is a heterodimeric com-
plex composed of three alpha subunits (HIF-1α, HIF-2α,
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as aryl hydrocarbon receptor nuclear translocator (ARNT))
[42]. Hypoxic HIF activity is controlled primarily through
post-translational modification and stabilization of the
HIF-1α and HIF-2α subunits, and HIF-1β expression
levels constitute important determinants of hypoxia re-
sponsiveness [42]. It is well known that heterodimeric
complexes of HIF-1α/β translocate to the nucleus and ac-
tivate several hypoxia-associated genes, including VEGF
[16]. VEGF-A can form homodimers with itself and/or
heterodimers with PIGF, and acts by binding to its two
cell surface tyrosine kinase receptors, FLT-1 (VEGFR1)
and KDR/FLK-1 (VEGFR2). PIGF binds only to FLT-1
(VEGFR1) [16]. Thus, implantation in the Fallopian tube
leads to the coordinated activation of a transcriptional cas-
cade in response to the presence of excessive hypoxia. As a
result, tubal VEGF-A levels are increased and this activates
the VEGF signaling cascades in an autocrine manner. On
the other hand, increased levels of tubal VEGF causes them
to be released into the circulation, and this leads to activa-
tion of the VEGF signaling cascades in a paracrine manner.
Both autocrine and paracrine regulation may result in tubal
fluid secretion, vascular defects, angiogenic dysfunction,
and tubal wall damage. During normal pregnancy, VEGF
isoforms are involved in building the placenta [16]. VEGF-
A is expressed in the human placenta throughout gestation
[43], and placenta-specific PIGF has a similar role as VEGF
during normal IUP [16]. We show that serum PIGF levels
are significantly increased in the middle and late stages of
IUP compared to the early stage of IUP. In contrast to
VEGF-A, however, we were unable to find a significant dif-
ference in serum PIGF levels between women with tubal
EP and gestational age-matched women with IUP. Some
previous studies have indicated that serum PIFG levels are
elevated in tubal EP compared to IUP [23,24]. This discrep-
ancy may be due to the different ethnic backgrounds of the
patients analyzed, the pooling of blood samples from differ-
ent gestational-aged women with acute and chronic clinical
presentation of EP, and the use of a non-gestational age-
matched IUP as a comparison control.
E2 has traditionally been considered the major hormo-
nal regulator of the Fallopian tube [34]. E2 exerts its bio-
logical effects by binding to the estrogen receptor (ER),
which exists as two different subtypes, ERα and ERβ.
Both ER subtypes are expressed in normal human Fallo-
pian tubes [5,44-46]. Moreover, ERα is frequently lost in
the implantation and non-implantation site (our unpub-
lished data) of the Fallopian tube in women who have
suffered from EP [44,47]. Although the VEGF gene pro-
moter harbors the estrogen response element [47],
whether E2 is able to directly regulate VEGF-A expres-
sion via the activation of ER signaling in human Fallopian
tubes is not fully understood. On the other hand, animal
studies suggest that E2 and hypoxia can cooperate toregulate the same target in the Fallopian tube. For ex-
ample, the expression of erythropoietin, a potent anti-
inflammatory cytokine, is increased by both E2 and hyp-
oxia in mouse Fallopian tubes both in vivo and in vitro
[48]. Treatment with E2 followed by hypoxic stimulation
significantly reduces VEGF-A protein synthesis and re-
lease in human endometrial tissues in vitro [49]. Because
the C-terminal domain of HIF-1β, a potent coactivator of
ER-dependent transcription, is essential for the enhance-
ment of ER transcription [50], E2-dependent regulation of
VEGF expression and secretion may be indirect through
HIF isoforms during the Fallopian tubal implantation. Fur-
thermore, in vitro experiments have shown that insulin-
like growth factor-1 and interleukin-1β directly regulate
VEGF and VEGFR expression in human tubal epithelial
cells and stromal fibroblasts [51,52]. Collectively, these
observations show that different molecules contribute to
the regulation of VEGF synthesis and secretion, but their
precise roles in tubal EP are not clearly understood. No
existing mouse models can establish causative roles for
factors implicated in the pathogenesis of EP [1,9], thus
new animal models will need to be developed to specific-
ally address these issues.
Although placenta-specific ADAM12 has been previ-
ously reported to distinguish EP from IUP [12,26], our
findings are in agreement with a recent finding by Horne
et al. [27] that demonstrated the limited utility of single
serum ADAM12 measurements as an early diagnostic
biomarker for tubal EP.
Limitations to the study
A limitation of the study is the relatively small sizes of
the patient groups, and these may not accurately repre-
sent the actual biomarker levels during the development
and onset of tubal EP. Thus additional large-scale stud-
ies are needed to determine the changes in selected bio-
marker levels before onset of tubal EP to validate their
utility in diagnosing tubal EP. Because it is ethically impos-
sible to obtain tissues from early IUP and post-surgery EP
patients, another limitation is that our study lacks data
using Western blotting analysis and immunohistochemistry
for determining VEGF-A, PIGF, and ADAM12 expression
levels in these patients.
Conclusions
In summary, we have demonstrated that individual
measurements of serum E2 or VEGF-A levels are strongly
related to early pregnancy outcomes for women with IUP
and EP, and pregnancy-associated E2 and VEGF-A levels
may serve as biomarkers for the early diagnosis of tubal EP.
Although our study also highlights the potential use of
combined E2/VEGF-A or E2/PIGF measurements as prom-
ising diagnostic biomarkers for tubal EP, the limitations of
our study warrant further investigation. Further studies
Zou et al. Journal of Translational Medicine 2013, 11:44 Page 11 of 12
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defined and gestational age-matched tubal EP and IUP are
warranted to confirm the clinical relevance of these
correlations in women with tubal EP.
Abbreviations
EP: Ectopic pregnancy; IUP: Intrauterine pregnancy; E2: 17β-estradiol;
P4: Progesterone; T: Testosterone; β-hCG: Beta-human chorionic
gonadotropin; VEGF-A: Vascular endothelial growth factor-A; PIGF: Placental
growth factor; ADAM12: A distintegrin and metalloprotease protein 12.
Competing interests
The authors report no conflict of interest.
Authors’ contributions
SZ, XL, YF, SS, JL, and EE participated in the recruitment of patients,
conducted the experiments, performed statistical analysis of the data, and
made the tables and figures. HB provided clinical insights, interpreted the
data, and edited the paper. RS designed, supervised and coordinated the
study and drafted the manuscript. Each author has taken public
responsibility for appropriate portions of the content and all authors have
read and approved the final manuscript.
Acknowledgments
We thank Prof. Shaofen Zhang and Dr. Yu Ding (Department of Gynecology,
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China) for
their valuable comments on the manuscript and discussion during the
current investigation.
Funding
This work was supported by the Swedish Medical Research Council (Grants
5859), the Sahlgrenska Academy Research Council, GöteborgsLäkaresällskap,
the HjalmarSvensson Foundation, Fred G. and Emma E. Kanold’s Foundation,
Fredrik and Ingrid Thuring’s Foundation, Anna Cederberg’s Foundation, Tore
Nilson’s Foundation, ÅkeWiberg’s Foundation, Wilhelm-Martina Lundgren’s
Foundation, the Wennergren Foundation, Jane and Dan Olsson’s Foundation,
and the Royal Society of Arts and Sciences in Gothenburg. The funding
sources of this study were not involved in the study design, collection,
analysis, or data interpretation, in the writing of the report, or in the decision
to submit the paper for publication.
Author details
1Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan
University, Shanghai 200011, China. 2Department of Physiology/
Endocrinology, Institute of Neuroscience and Physiology, The Sahlgrenska
Academy, University of Gothenburg, Gothenburg 40530, Sweden.
3Department of Integrative Medicine and Neurobiology, State Key Lab of
Medical Neurobiology, Shanghai Medical College and Institute of
Acupuncture Research (WHO Collaborating Center for Traditional Medicine),
Institute of Brain Science, Fudan University, Shanghai 200032, China.
4Laboratory Center, Eye and Ear, Nose, Throat Hospital of Fudan University,
Shanghai 200031, China. 5Institute of Bioscience, Fudan University, Shanghai
200032, China.
Received: 28 November 2012 Accepted: 7 February 2013
Published: 19 February 2013
References
1. Shaw JL, Dey SK, Critchley HO, Horne AW: Current knowledge of the
aetiology of human tubal ectopic pregnancy. Hum Reprod Update 2010,
16:432–444.
2. Barnhart KT: Clinical practice. Ectopic pregnancy. N Engl J Med 2009,
361:379–387.
3. Farquhar CM: Ectopic pregnancy. Lancet 2005, 366:583–591.
4. Jurkovic D, Wilkinson H: Diagnosis and management of ectopic
pregnancy. BMJ 2011, 342:d3397.
5. Shao R, Feng Y, Zou S, Weijdegard B, Wu G, Brannstrom M, Billig H: The role
of estrogen in the pathophysiology of tubal ectopic pregnancy. Am J
Transl Res 2012, 4:269–278.6. Shao R, Wang X, Wang W, Stener-Victorin E, Mallard C, Brannstrom M, Billig H:
From mice to women and back again: Causalities and clues for Chlamydia-
induced tubal ectopic pregnancy. Fertil Steril 2012, 98:1175–1185.
7. Shao R, Zhang SX, Weijdegard B, Zou S, Egecioglu E, Norstrom A,
Brannstrom M, Billig H: Nitric oxide synthases and tubal ectopic
pregnancies induced by Chlamydia infection: basic and clinical insights.
Mol Hum Reprod 2010, 16:907–915.
8. Shao R, Zou S, Wang X, Feng Y, Brannstrom M, Stener-Victorin E, Billig H:
Revealing the Hidden Mechanisms of Smoke-Induced Fallopian Tubal
Implantation. Biol Reprod 2012, 86:131.
9. Shao R: Understanding the mechanisms of human tubal ectopic
pregnancies: new evidence from knockout mouse models. Hum Reprod
2010, 25:584–587.
10. Cabar FR, Fettback PB, Pereira PP, Zugaib M: Serum markers in the
diagnosis of tubal pregnancy. Clinics (Sao Paulo) 2008, 63:701–708.
11. Gerton GL, Fan XJ, Chittams J, Sammel M, Hummel A, Strauss JF, Barnhart K:
A serum proteomics approach to the diagnosis of ectopic pregnancy.
Ann N Y Acad Sci 2004, 1022:306–316.
12. Rausch ME, Sammel MD, Takacs P, Chung K, Shaunik A, Barnhart KT:
Development of a multiple marker test for ectopic pregnancy. Obstet
Gynecol 2011, 117:573–582.
13. Segal S, Mercado R, Rivnay B: Ectopic pregnancy early diagnosis markers.
Minerva Ginecol 2010, 62:49–62.
14. Barnhart K, Speicher DW: Molecular diagnosis of ectopic pregnancy. Expert
Rev Mol Diagn 2011, 11:759–762.
15. Cartwright J, Duncan WC, Critchley HO, Horne AW: Serum biomarkers of
tubal ectopic pregnancy: current candidates and future possibilities.
Reproduction 2009, 138:9–22.
16. Andraweera PH, Dekker GA, Roberts CT: The vascular endothelial growth
factor family in adverse pregnancy outcomes. Hum Reprod Update 2012,
18:436–457.
17. Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM: Cellular roles of
ADAM12 in health and disease. Int J Biochem Cell Biol 2008, 40:1685–1702.
18. Daniel Y, Geva E, Lerner-Geva L, Eshed-Englender T, Gamzu R, Lessing JB,
Bar-Am A, Amit A: Levels of vascular endothelial growth factor are
elevated in patients with ectopic pregnancy: is this a novel marker? Fertil
Steril 1999, 72:1013–1017.
19. Daponte A, Pournaras S, Zintzaras E, Kallitsaris A, Lialios G, Maniatis AN,
Messinis IE: The value of a single combined measurement of VEGF,
glycodelin, progesterone, PAPP-A, HPL and LIF for differentiating
between ectopic and abnormal intrauterine pregnancy. Hum Reprod
2005, 20:3163–3166.
20. Fasouliotis SJ, Spandorfer SD, Witkin SS, Liu HC, Roberts JE, Rosenwaks Z:
Maternal serum vascular endothelial growth factor levels in early ectopic
and intrauterine pregnancies after in vitro fertilization treatment. Fertil
Steril 2004, 82:309–313.
21. Felemban A, Sammour A, Tulandi T: Serum vascular endothelial growth
factor as a possible marker for early ectopic pregnancy. Hum Reprod
2002, 17:490–492.
22. Mueller MD, Raio L, Spoerri S, Ghezzi F, Dreher E, Bersinger NA: Novel
placental and nonplacental serum markers in ectopic versus normal
intrauterine pregnancy. Fertil Steril 2004, 81:1106–1111.
23. Patrelli TS, Gizzo S, Plebani M, Basso D, Capobianco G, Bartolucci C, Modena
AB, Rondinelli M, Nardelli GB: The trend of VEGF-A and PlGF in pregnant
patients: a perspective case–control study on 214 women. Clin Exp Obstet
Gynecol 2012, 39:57–64.
24. Daponte A, Pournaras S, Polyzos NP, Tsezou A, Skentou H, Anastasiadou F,
Lialios G, Messinis IE: Soluble FMS-like tyrosine kinase-1 (sFlt-1) and serum
placental growth factor (PlGF) as biomarkers for ectopic pregnancy and
missed abortion. J Clin Endocrinol Metab 2011, 96:E1444–E1451.
25. Horne AW, Shaw JL, Murdoch A, McDonald SE, Williams AR, Jabbour HN,
Duncan WC, Critchley HO: Placental growth factor: a promising diagnostic
biomarker for tubal ectopic pregnancy. J Clin Endocrinol Metab 2011,
96:E104–E108.
26. Beer LA, Tang HY, Sriswasdi S, Barnhart KT, Speicher DW: Systematic
discovery of ectopic pregnancy serum biomarkers using 3-day protein
profiling coupled with label-free quantitation. J Proteome Res 2011,
10:1126–1138.
27. Horne AW, Brown JK, Tong S, Kaitu'u-Lino T: Evaluation of ADAM-12 as a
Diagnostic Biomarker of Ectopic Pregnancy in Women with a Pregnancy
of Unknown Location. PLoS One 2012, 7:e41442.
Zou et al. Journal of Translational Medicine 2013, 11:44 Page 12 of 12
http://www.translational-medicine.com/content/11/1/4428. Rausch ME, Beer L, Sammel MD, Takacs P, Chung K, Shaunik A, Speicher D,
Barnhart KT: A disintegrin and metalloprotease protein-12 as a novel marker
for the diagnosis of ectopic pregnancy. Fertil Steril 2011, 95:1373–1378.
29. Kucera-Sliutz E, Schiebel I, Konig F, Leodolter S, Sliutz G, Koelbl H: Vascular
endothelial growth factor (VEGF) and discrimination between abnormal
intrauterine and ectopic pregnancy. Hum Reprod 2002, 17:3231–3234.
30. Noyes RW, Hertig AT, Rock J: Dating the endometrial biopsy. Am J Obstet
Gynecol 1975, 122:262–263.
31. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a
fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561–577.
32. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics 1988, 44:837–845.
33. Craig ZG, Ramey JM, Rochowiak MW, Brown LH, Teitelbaum H: Serum
estradiol in the differential diagnosis of ectopic pregnancy. J Am
Osteopath Assoc 1996, 96:461–464.
34. Wang H, Dey SK: Roadmap to embryo implantation: clues from mouse
models. Nat Rev Genet 2006, 7:185–199.
35. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB: Vascular endothelial growth
factor localization in human ovary and fallopian tubes: possible role in
reproductive function and ovarian cyst formation. J Clin Endocrinol Metab
1996, 81:353–359.
36. Lam PM, Briton-Jones C, Cheung CK, Lok IH, Yuen PM, Cheung LP, Haines C:
Vascular endothelial growth factor in the human oviduct: localization
and regulation of messenger RNA expression in vivo. Biol Reprod 2003,
68:1870–1876.
37. Lam PM, Briton-Jones C, Cheung CK, Po LS, Cheung LP, Haines C: Increased
mRNA expression of vascular endothelial growth factor and its receptor
(flt-1) in the hydrosalpinx. Hum Reprod 2003, 18:2264–2269.
38. Itoh H, Nasu K, Matsumoto H, Kawano Y, Yoshimatsu J, Narahara H: Hypoxia
regulates vascular endothelial growth factor and soluble fms-like
tyrosine kinase-1 secretion by human oviductal epithelial cells and
stromal fibroblasts. Fertil Steril 2006, 85(Suppl 1):1097–1102.
39. Lam PM, Briton-Jones C, Cheung CK, Leung SW, Cheung LP, Haines C:
Increased messenger RNA expression of vascular endothelial growth
factor and its receptors in the implantation site of the human oviduct
with ectopic gestation. Fertil Steril 2004, 82:686–690.
40. Cabar FR, Pereira PP, Schultz R, Francisco RP, Zugaib M: Vascular
endothelial growth factor and beta-human chorionic gonadotropin are
associated with trophoblastic invasion into the tubal wall in ectopic
pregnancy. Fertil Steril 2010, 94:1595–1600.
41. Kilic S, Tasdemir N, Lortlar N, Yuksel B, Budak G, Batioglu S: Vascular
endothelial growth factor (VEGF) and inducible nitric oxide synthase
(iNOS) immunoreactivities in rat ovaries and uterine tubes after tubal
ligation: a controlled immunohistochemical study. Eur J Contracept Reprod
Health Care 2008, 13:431–437.
42. Ke Q, Costa M: Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006,
70:1469–1480.
43. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS: Comparison of
expression patterns for placenta growth factor, vascular endothelial
growth factor (VEGF), VEGF-B and VEGF-C in the human placenta
throughout gestation. J Endocrinol 1998, 159:459–467.
44. Horne AW, King AE, Shaw E, McDonald SE, Williams AR, Saunders PT,
Critchley HO: Attenuated sex steroid receptor expression in fallopian
tube of women with ectopic pregnancy. J Clin Endocrinol Metab 2009,
94:5146–5154.
45. Shao R, Norstrom A, Weijdegard B, Egecioglu E, Fernandez-Rodriguez J,
Feng Y, Stener-Victorin E, Brannstrom M, Billig H: Distinct Expression
Pattern of Dicer1 Correlates with Ovarian-Derived Steroid Hormone
Receptor Expression in Human Fallopian Tubes during Ovulation and
the Midsecretory Phase. J Clin Endocrinol Metab 2011, 96:E869–E877.
46. Shao R, Wang X, Weijdegard B, Norstrom A, Fernandez-Rodriguez J,
Brannstrom M, Billig H: Coordinate regulation of heterogeneous nuclear
ribonucleoprotein dynamics by steroid hormones in the human
Fallopian tube and endometrium in vivo and in vitro. Am J Physiol
Endocrinol Metab 2012, 302:E1269–E1282.
47. Ulziibat S, Ejima K, Shibata Y, Hishikawa Y, Kitajima M, Fujishita A, Ishimaru T,
Koji T: Identification of estrogen receptor beta-positive intraepithelial
lymphocytes and their possible roles in normal and tubal pregnancy
oviducts. Hum Reprod 2006, 21:2281–2289.48. Masuda S, Kobayashi T, Chikuma M, Nagao M, Sasaki R: The oviduct
produces erythropoietin in an estrogen- and oxygen-dependent
manner. Am J Physiol Endocrinol Metab 2000, 278:E1038–E1044.
49. Punyadeera C, Thijssen VL, Tchaikovski S, Kamps R, Delvoux B, Dunselman
GA, de Goeij AF, Griffioen AW, Groothuis PG: Expression and regulation of
vascular endothelial growth factor ligands and receptors during
menstruation and post-menstrual repair of human endometrium. Mol
Hum Reprod 2006, 12:367–375.
50. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I: The
basic helix-loop-helix-PAS protein ARNT functions as a potent
coactivator of estrogen receptor-dependent transcription. Proc Natl Acad
Sci U S A 2003, 100:6517–6522.
51. Nasu K, Itoh H, Yuge A, Kawano Y, Narahara H: Insulin-like growth factor-I
regulates vascular endothelial growth factor secretion by human
oviductal epithelial cells and stromal fibroblasts. J Soc Gynecol Investig
2006, 13:368–371.
52. Nasu K, Itoh H, Yuge A, Kawano Y, Yoshimatsu J, Narahara H: Interleukin-
1beta regulates vascular endothelial growth factor and soluble fms-like
tyrosine kinase-1 secretion by human oviductal epithelial cells and
stromal fibroblasts. Gynecol Endocrinol 2006, 22:495–500.
doi:10.1186/1479-5876-11-44
Cite this article as: Zou et al.: Comparison of the diagnostic values of
circulating steroid hormones, VEGF-A, PIGF, and ADAM12 in women
with ectopic pregnancy. Journal of Translational Medicine 2013 11:44.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
